Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 864-870

  Rose, Christian ^a   Brechignac, Sabine ^b   Vassilief, Dominique ^c   Pascal, Laurent ^a   Stamatoullas, Aspasia ^d   Guerci, Agnes ^e   Larbaa, Dalila ^f   Dreyfus, François ^c   Beyne Rauzy, Odile ^g   Chaury, Marie Pierre ^h   Roy, Lydie ⁱ   Cheze, Stephane ^j   Morel, Pierre ^k   Fenaux, Pierre ^b  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c Hôpital Cochin ^*  (France)

^d CENTRE HENRI BECQUEREL   (France)

^e CHU NANCY BRABOIS   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g CHU PURPAN   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k Centre Hospitalier de LENS   (France)

more..

Author keywords

Iron chelation therapy; Myelodysplastic syndrome; Survival; Transfusion

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

AGED; ARTICLE; BLOOD TRANSFUSION; CAUSE OF DEATH; CHELATION THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77952959079     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.004     Document Type: Article

References (45)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51(June(2)):189-199.
2. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000, 13(February(2)):193-207.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(March(6)):2079-2088.
4. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(October(30)):7594-7603.
5. Porta MGD, Kuendgen A, Malcovati L, Zipperer E, Pascutto C, Travaglino E, et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. (abs2677). Blood; 2008:112a.
6. Asmis T.R., Ding K., Seymour L., Shepherd F.A., Leighl N.B., Winton T.L., et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008, 26(January(1)):54-59.
7. Sorror M., Storer B., Sandmaier B.M., Maloney D.G., Chauncey T.R., Langston A., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008, 112(May(9)):1992-2001.
8. Park S., Grabar S., Kelaidi C., Beyne-Rauzy O., Picard F., Bardet V., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111(January(2)):574-582.
9. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(October(14)):1456-1465.
10. Gupta P., LeRoy S.C., Luikart S.D., Bateman A., Morrison V.A. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999, 23(October(10)):953-959.
11. Heaney M.L., Golde D.W. Myelodysplasia. N Engl J Med 1999, 340(May(21)):1649-1660.
12. Cazzola M., Della Porta M.G., Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2008, 166-175.
13. Kersten M.J., Lange R., Smeets M.E., Vreugdenhil G., Roozendaal K.J., Lameijer W., et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996, 73(November(5)):247-252.
14. Porter J., Galanello R., Saglio G., Neufeld E.J., Vichinsky E., Cappellini M.D., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80(February(2)):168-176.
15. Remacha A.F., Arrizabalaga B., Del Canizo C., Sanz G., Villegas A. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2009, August.
16. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91(December(12)):1588-1590.
17. Chee C.E., Steensma D.P., Wu W., Hanson C.A., Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008, 83(August(8)):611-613.
18. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109(May(10)):4586-4588.
19. Boultwood J., Lewis S., Wainscoat J.S. The 5q-syndrome. Blood 1994, 84(November(10)):3253-3260.
20. Cazzola M., Barosi G., Gobbi P.G., Invernizzi R., Riccardi A., Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988, 71(February(2)):305-312.
21. Schafer A.I., Cheron R.G., Dluhy R., Cooper B., Gleason R.E., Soeldner J.S., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304(February(6)):319-324.
22. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331(September(9)):567-573.
23. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331(September(9)):574-578.
24. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94(August(2)):288-299.
25. Leitch H.A., Leger C.S., Goodman T.A., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2:205-211.
26. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007, 78(June(6)):487-494.
27. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(November(11)):858-861.
28. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007, 31(December(Suppl. 3)):S10-S15.
29. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 405:373-383.
30. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007, 31(December(Suppl. 3)):S7-S9.
31. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., et al. Retrospective survey of Japanese patients with transfusion-dependent myelodysplastic syndromes ans aplastic anemia highlights the negetive impact of iron overload on morbidity/mortality. (abs 2656). Blood 2006, 10811:751a.
32. Sanz G., Nomdedeu B., Such E., Bernal T., Belkaid M., Ardanaz M.T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. (abs 640). Blood 2008, 11211:238.
33. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, August.
34. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003, 533(December(1-2)):153-171.
35. Valle P., Timeus F., Piglione M., Rosso P., di Montezemolo L.C., Crescenzio N., et al. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 1995, 12(September-October(5)):439-446.
36. Ohyashiki J.H., Kobayashi C., Hamamura R., Okabe S., Tauchi T., Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009, 100(May(5)):970-977.
37. Lovejoy D.B., Richardson D.R. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003, 10(June(12)):1035-1049.
38. Selig R.A., Madafiglio J., Haber M., Norris M.D., White L., Stewart B.W. Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines. Anticancer Res 1993, 13(May-June (3)):721-725.
39. Boelaert J.R., de Locht M., Van Cutsem J., Kerrels V., Cantinieaux B., Verdonck A., et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993, 91(May(5)):1979-1986.
40. Chacko J., Pennell D.J., Tanner M.A., Hamblin T.J., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007, 138(September(5)):587-593.
41. Di Tucci A.A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93(September(9)):1385-1388.
42. Ferte C., Ernst O., Beyne-Rauzy O., Chaury S., Brechignac S., Brauner M., et al. Clinical relevance of cardiac iron overload estimated by MRI T2 in regularly transfused low risk MDS. (abs.2666). Blood 2006, 10811:753a.
43. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007, 82(November(11)):1013-1016.
44. Jensen P.D., Jensen F.T., Christensen T., Eiskjaer H., Baandrup U., Nielsen J.L. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003, 101(June(11)):4632-4639.
45. Jensen P.D., Jensen I.M., Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992, 80(January(1)):121-124.